RxDoctor Payments Data

Paul Bristol, MD

Family Medicine · Austin, TXNPI 1780760595

Payments from drug & device makers

$1,921in general payments, 2019–2025

Across 110 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$377
  • Lilly USA, LLC$269
  • AbbVie$247
  • AstraZeneca$193
  • Boehringer Ingelheim$152
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$136
  • plus $548 from 11 others

What the payments were for

  • Food & beverage$1,90199%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,921 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$20,191
Medicare patients
76
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide64$70,878
JanuviaSitagliptin Phosphate29$42,295
MounjaroTirzepatide35$38,086
OzempicSemaglutide12$28,367
RybelsusSemaglutide16$21,352
FarxigaDapagliflozin Propanediol19$16,664
EliquisApixaban16$14,735
JardianceEmpagliflozin15$11,030
Rosuvastatin Calcium338$4,856
Nebivolol Hcl66$2,893
SynthroidLevothyroxine Sodium30$2,553
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide82$2,282
Clonidine30$1,087
Ezetimibe32$1,059
Azelastine-FluticasoneAzelastine/Fluticasone12$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$269$108,96599 claims
Novo NordiskOzempic, Rybelsus$99$49,71928 claims
AstraZenecaFarxiga$193$16,66419 claims
PfizerEliquis$16$14,73516 claims
Boehringer IngelheimJardiance$152$11,03015 claims
AbbVieSynthroid$247$2,55330 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$44836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →